News

FDA Approves Single-Dose fosaprepitant dimeglumine

2016 Medicare Updates.

This webinar is part of The Amgen Assist^®Learning Tree, which is designed to provide a variety of access and reimbursement information. Topics for this webinar will include updates to the 2016 Medicare Physician Fee Schedule and Outpatient Prospective Payment System as they relate to Amgen Oncology, as well as other Coding and Medicare developments of relevance to practice managers.

Regional Educational Programs

http://www.asco.org/advocacy/asco-joins-physician-clinical-registry-coalition-letter-regarding-senate-hit-legislation

Check out this new informative video and plan to join us for the 1st annual poster session at this year's spring meeting!

https://www.facebook.com/NNECOS/videos/786569938142354/ 

2016 Spring Meeting

http://nnecos.org/FDA

• Approval of eribulin - liposarcoma
• Expanded approval of nivolumab and ipilimumab
  

https://www.une.edu/news/2015/une-dpt-students-present-project-oncology-team-central-maine-comprehensive-cancer-center

We want to hear about your efforts to enhance quality, care delivery, and the patient experience. Share your innovative project, program or best practice!

Spring Meeting Abstracts

Nursing Considerations for the Management of Patients with Multiple Myeloma

Check out our drug related resources pages!

FDA Approvals

Code Updates

Packaging/Label Updates

On December 18, 2015, the U. S. Food and Drug Administration (FDA) expanded the label to include the approval of pembrolizumab (Keytruda® Injection, Merck Sharp & Dohme Corp.) for the treatment of patients with unresectable or metastatic melanoma. This expansion now includes the initial treatment of patients with unresectable or metastatic melanoma with pembrolizumab. More information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm478493.htm